0000950170-23-047530.txt : 20230911
0000950170-23-047530.hdr.sgml : 20230911
20230911174220
ACCESSION NUMBER: 0000950170-23-047530
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230907
FILED AS OF DATE: 20230911
DATE AS OF CHANGE: 20230911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brady Todd C
CENTRAL INDEX KEY: 0001579179
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 231248583
MAIL ADDRESS:
STREET 1: C/O EVOKE PHARMA, INC.
STREET 2: 505 LOMAS SANTA FE DRIVE
CITY: SOLANA BEACH
STATE: CA
ZIP: 92075
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
ownership.xml
4
X0508
4
2023-09-07
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001579179
Brady Todd C
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE
LEXINGTON
MA
02421
true
true
false
false
President and CEO
false
Common Stock
2023-09-07
4
M
false
192084
0.552
A
1647369
D
Common Stock
2023-09-07
4
M
false
32953
0.552
A
1680322
D
Common Stock
2023-09-07
4
M
false
48021
0.552
A
1728343
D
Common Stock
2023-09-07
4
F
false
73807
7.22
D
1654536
D
Stock Option (right to buy)
0.552
2023-09-07
4
M
false
192084
0.00
D
2023-09-07
Common Stock
192084
0
D
Stock Option (right to buy)
0.552
2023-09-07
4
M
false
32953
0.00
D
2023-09-07
Common Stock
32953
0
D
Stock Option (right to buy)
0.552
2023-09-07
4
M
false
48021
0.00
D
2023-09-07
Common Stock
48021
0
D
Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the exercise of the stock options.
The stock option is fully vested.
/s/ Todd C. Brady
2023-09-11